- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT04756830
A Study to Assess the Safety and Immunogenicity of the Coronavac Vaccine Against COVID-19
An Open-label Uncontrolled Study to Assess the Safety and Immunogenicity of the Inactivated Adsorbed Vaccine Against COVID-19 (Coronavac) in Individuals Over 18 Years of Age During 24 Months of Follow-up
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
This is an open-label uncontrolled study in which all participants will receive two doses of the inactivated adsorbed vaccine against COVID-19, and will be followed up for safety and immunogenicity analysis for 24 months. This study will assess safety and immunogenicity of the inactivated vaccine adsorbed against COVID-19 (CoronaVac) in a population of healthy individuals older than 18 years of age.
The estimated number of participants is 1200. Participants will be recruited within 3-4 months. The total duration of the study is estimated to be 30 months after recruitment begins.
The participants will remain in the study for approximately 24 months. The study will be carried out at the clinical research center of the D'Or Institute for Research and Education (IDOR) located at the Hospital Glória D'Or, in the city of Rio de Janeiro, RJ, Brazil
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Fase 4
Kontakter og lokationer
Studiesteder
-
-
-
Rio De Janeiro, Brasilien, 22211-230
- Hospital Gloria D'Or - Hospitais Integrados da Gavea S/A
-
Rio De Janeiro, Brasilien, 22281100
- D'Or Institute for Research and Education
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Adults 18 years of age or older;
- Agree with study procedures after reading and signing the Informed Consent Form
Exclusion Criteria:
- Pregnancy (confirmed by positive β-hCG test), breastfeeding and / or expressing intention to have sexual practices with reproductive potential without using contraceptive methods in the three months following vaccination
- Evidence of uncontrolled neurological, cardiac, pulmonary, hepatic or renal disease, according to anamnesis or physical examination. Significant changes in treatment or hospitalizations due to worsening of the condition in the last three months are indicators of uncontrolled disease;
- Diseases with impaired immune system including: neoplasms (except basal cell carcinoma), congenital or acquired immunodeficiencies and autoimmune diseases not controlled according to anamnesis or physical examination. Significant changes in treatment or hospitalizations due to worsening of the condition in the last three months are indicators of uncontrolled disease;
- Behavioral, cognitive or psychiatric illness that, in the opinion of the principal investigator or his medical representative, affects the participant's ability to understand and collaborate with the requirements of the study protocol
- Any alcohol or drug abuse in the last 12 months prior to inclusion in the study that has caused medical, professional or family problems, as indicated by clinical history;
- History of severe allergic reaction or anaphylaxis to the vaccine or components of the study vaccine;
- History of asplenia;
- Participation in another clinical trial with product administration under investigation during the six months prior to its inclusion in the study or scheduled participation in another clinical trial in the two years following inclusion;
- Previous participation in a COVID-19 vaccine evaluation study or previous exposure to a COVID-19 vaccine;
- Use of immunosuppressive therapies six months prior to inclusion in the study or its scheduled use within two years of inclusion. Immunosuppressive therapies will be considered: antineoplastic chemotherapy, radiation therapy, immunosuppressants to induce tolerance to transplants, among others.
- Have received an immunosuppressive dose of corticosteroids in the last three months prior to inclusion in the study or scheduled administration of an immunosuppressive dose of corticosteroids for the three months following inclusion in the study. The dose of corticosteroids considered immunosuppressive is equivalent to prednisone at a dose of 20 mg / day for adults, for more than a week. The continuous use of topical or nasal corticosteroids is not considered immunosuppressive;
- Have received blood products (transfusions or immunoglobulins) in the last three months before inclusion in the study, or scheduled administration of blood products or immunoglobulin in the two years following inclusion in the study;
- Suspected or confirmed fever within 72 hours prior to vaccination or axillary temperature greater than 37.8 ° C * on the day of vaccination (inclusion may be postponed until the participant completes 72 hours without fever);
- Possible or confirmed case of COVID-19 on the day of vaccination (vaccination can be postponed until the participant completes 72 hours without symptoms or the diagnosis is ruled out);
- Have received vaccine with live attenuated virus in the last 28 days or inactivated vaccine in the last 14 days prior to their inclusion in the study, or have immunization scheduled for the first 28 days after their inclusion in the study;
- History of bleeding disorders (for example, deficiency of clotting factors, coagulopathy, platelet dysfunction), or previous history of bleeding or significant bruising after IM injection or venipuncture.
- Any other condition that, in the opinion of the principal investigator or his medical representative, could jeopardize the safety or rights of a potential participant or that would prevent him from complying with this protocol.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Forebyggelse
- Tildeling: N/A
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
---|---|
Andet: Vaccination
All participants will receive two doses of the inactivated adsorbed vaccine against COVID-19.
|
Participants will receive two doses with 14-days interval of adsorbed COVID-19 (inactivated) vaccine
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Frequency of local and systemic adverse reactions in the first 7 days after immunization
Tidsramme: Seven days after each immunization
|
Frequency of solicited and unsolicited local and systemic adverse reactions in the first 7 days after vaccination per age group (18-59 years old and 60 years old or older), attributed to the vaccine after causality assessment
|
Seven days after each immunization
|
Seroconversion rates
Tidsramme: Two weeks after the second immunization
|
Seroconversion rates in the second week after the second dose of the vaccine per age group (18-59 years and 60 years old or older).
|
Two weeks after the second immunization
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Frequency of adverse reactions up to 28 days after immunization
Tidsramme: 28 days after the second immunization
|
Frequency of unsolicited local and systemic adverse reactions up to 28 days after the second dose of the vaccine per age group (18-59 years old and 60 years old or older), attributed to the vaccine after causality assessment
|
28 days after the second immunization
|
Frequency of severe adverse events
Tidsramme: Up to 12 months after first immunization
|
Frequency of severe adverse events after vaccination, attributed to the vaccine after causality assessment
|
Up to 12 months after first immunization
|
Frequency of adverse events of special interest
Tidsramme: Up to 12 months after first immunization
|
Frequency of adverse events of special interest after receiving, at least, one dose of the vaccine
|
Up to 12 months after first immunization
|
Cell-mediated immune response
Tidsramme: At inclusion and 4 weeks after the second vaccination
|
Cell-mediated immune response at inclusion and four weeks after the second vaccination per age group (18-59 years old and 60 years old or older).
|
At inclusion and 4 weeks after the second vaccination
|
Frequency of detection of antibodies against SARS-CoV-2
Tidsramme: At inclusion, and two weeks, 6 months, 12 months, 18 months and 24 months after the second vaccination
|
Frequency of detection of antibodies against SARS-CoV-2 at inclusion, and two weeks, 6 months, 12 months, 18 months and 24 months after the second dose of the vaccine against COVID-19.
|
At inclusion, and two weeks, 6 months, 12 months, 18 months and 24 months after the second vaccination
|
Geometric mean titer of neutralizing antibodies
Tidsramme: At inclusion, and two weeks, 6 months, 12 months, 18 months and 24 months after the second vaccination
|
Geometric mean titer of neutralizing antibodies against SARS-CoV-2 at inclusion, and two weeks, 6 months, 12 months, 18 months and 24 months after the second dose of the vaccine against COVID-19.
|
At inclusion, and two weeks, 6 months, 12 months, 18 months and 24 months after the second vaccination
|
Andre resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Frequency of confirmed cases of COVID-19
Tidsramme: Up to 24 months after inclusion
|
Frequency of confirmed cases of COVID-19 per age group (18-59 years old and 60 years old or older) over 24 months.
|
Up to 24 months after inclusion
|
Frequency of SARS-CoV-2 variants of concern (VOC)
Tidsramme: Up to 24 months after inclusion
|
Frequency of SARS-CoV-2 variants of concern (VOC) in confirmed cases of COVID-19.
|
Up to 24 months after inclusion
|
Humoral and cellular immune response
Tidsramme: Up to 24 months after inclusion
|
Humoral and cellular immune response in confirmed cases of COVID-19
|
Up to 24 months after inclusion
|
Samarbejdspartnere og efterforskere
Samarbejdspartnere
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Forventet)
Studieafslutning (Forventet)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- IDOR_VAC_01
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med COVID-19
-
Yang I. PachankisAktiv, ikke rekrutterendeCOVID-19 luftvejsinfektion | COVID-19 stresssyndrom | COVID-19-vaccinebivirkning | COVID-19-associeret tromboembolisme | COVID-19 Post-Intensive Care Syndrome | COVID-19-associeret slagtilfældeKina
-
University of Roma La SapienzaQueen Mary University of London; Università degli studi di Roma Foro Italico og andre samarbejdspartnereAfsluttetPostakutte følgesygdomme af COVID-19 | Tilstand efter COVID-19 | Langtids-COVID | Kronisk COVID-19 syndromItalien
-
Massachusetts General HospitalRekrutteringPostakut COVID-19 syndrom | Lang COVID | Postakutte følgesygdomme af COVID-19 | Lang COVID-19Forenede Stater
-
Indonesia UniversityRekrutteringPost-COVID-19 syndrom | Lang COVID | Tilstand efter COVID-19 | Post-COVID syndrom | Lang COVID-19Indonesien
-
Dr. Soetomo General HospitalIndonesia-MoH; Universitas Airlangga; Biotis Pharmaceuticals, IndonesiaRekrutteringCovid-19-pandemi | Vacciner mod covid-19 | COVID-19 virus sygdomIndonesien
-
First Affiliated Hospital Xi'an Jiaotong UniversityShangluo Central Hospital; Ankang Central Hospital; Hanzhong Central Hospital og andre samarbejdspartnereRekrutteringKohorteopfølgning af epidemi og neuroimaging for patienter under den første bølge af COVID-19 i KinaCOVID-19 | Post-COVID-19 syndrom | Post-akut COVID-19 | Akut COVID-19Kina
-
Erasmus Medical CenterDa Vinci Clinic; HGC RijswijkIkke rekrutterer endnuPost-COVID-19 syndrom | Lang COVID | Lang Covid19 | Tilstand efter COVID-19 | Post-COVID syndrom | Tilstand efter COVID-19, uspecificeret | Post-COVID tilstandHolland
-
University of Witten/HerdeckeInstitut für Rehabilitationsforschung NorderneyAfsluttetPost-COVID-19 syndrom | Long-COVID-19 syndromTyskland
-
University Hospital, Ioannina1st Division of Internal Medicine, University Hospital of IoanninaRekrutteringCOVID-19 lungebetændelse | COVID-19 luftvejsinfektion | Covid-19-pandemi | COVID-19 Akut Respiratorisk Distress Syndrome | COVID-19-associeret lungebetændelse | COVID 19 associeret koagulopati | COVID-19 (Coronavirus sygdom 2019) | COVID-19-associeret tromboembolismeGrækenland
Kliniske forsøg med Adsorbed COVID-19 (inactivated) Vaccine
-
AstraZenecaAfsluttetCOVID-19Det Forenede Kongerige
-
Melike CengizAfsluttet
-
Hasanuddin UniversityChulalongkorn UniversityAfsluttet
-
Raphael SerreauAssistance Publique - Hôpitaux de Paris; University Hospital, Paris; François...AfsluttetCoronavirusinfektionFrankrig
-
AstraZenecaAfsluttetCovid-19Det Forenede Kongerige
-
University of PennsylvaniaPublic Health Management CorporationAfsluttet
-
University of Texas at AustinUkendtFødevareusikkerhedForenede Stater
-
University of PennsylvaniaPublic Health Management CorporationAfsluttet
-
Kanuni Sultan Suleyman Training and Research HospitalAyşegül Bestel; İbrahim Polat; Merve Aldıkaçtıoğlu TalmaçAfsluttetDepression, postpartum | Angst | COVIDKalkun
-
Duke UniversityNorth Carolina Department of Health and Human ServicesAfsluttetCOVID-19Forenede Stater